NCT06592274 A Phase 2 Study of HB0017 in Psoriasis Patients
| NCT ID | NCT06592274 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Huabo Biopharm Co., Ltd. |
| Condition | Psoriasis (PsO) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-09-30 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 200 participants in total. It began in 2024-09-30 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Eligibility Criteria
Inclusion Criteria: * Male or female subjects aged 18-75 years (inclusive) * Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization. * Psoriasis Area Severity Index (PASI) \&gt;=12 and body surface area (BSA) affected by PSO \&gt;=10% and Static Physician Global Assessment (sPGA) score \&gt;=3. * Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator * Subjects who are able to use effective contraception from the screening period to 6 months after the last dose Exclusion Criteria: * Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis * Ongoing use of prohibited treatments * Any active infection (other than common cold) within 14 days * Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization * Have previously received any drug that directly targets IL-17 or IL-17 receptor * Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization * A history of inflammatory bowel disease or other serious autoimmune disease * Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency
Frequently Asked Questions
Who can join the NCT06592274 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Psoriasis (PsO). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06592274 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06592274 currently recruiting?
Yes, NCT06592274 is actively recruiting participants. Visit ClinicalTrials.gov or contact Huabo Biopharm Co., Ltd. to inquire about joining.
Where is the NCT06592274 trial being conducted?
This trial is being conducted at Bengbu, China, Guangzhou, China, Changsha, China, Wuxi, China and 11 additional locations.
Who is sponsoring the NCT06592274 clinical trial?
NCT06592274 is sponsored by Huabo Biopharm Co., Ltd.. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.